Article
Oncology
Kevin Kalinsky, Fangxin Hong, Carolyn K. McCourt, Jasgit C. Sachdev, Edith P. Mitchell, James A. Zwiebel, L. Austin Doyle, Lisa M. McShane, Shuli Li, Robert J. Gray, Larry V. Rubinstein, David Patton, Paul M. Williams, Stanley R. Hamilton, Barbara A. Conley, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty
Summary: This study demonstrates that a clinically significant objective response rate was achieved in patients with an AKT1 E17K-mutated tumor treated with the pan-AKT inhibitor capivasertib, including one complete response.
Article
Oncology
Amy S. Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele, Edith P. Mitchell, James Zwiebel, Fernanda I. Arnaldez, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Mehmet S. Copur, Samer S. Kasbari, Ravneet Thind, Barbara A. Conley, Carlos L. Arteaga, Peter J. O'Dwyer, Lyndsay N. Harris, Alice P. Chen, Keith T. Flaherty
Summary: Cyclin D/CDK4/6 plays a critical role in controlling the G1 to S checkpoint. The gene encoding cyclin D, CCND, is known to be amplified in various solid tumors. Palbociclib, an oral CDK4/6 inhibitor, has been approved for the treatment of advanced breast cancer in combination with endocrine therapy. The efficacy of palbociclib in solid tumors with a CCND1, 2, or 3 amplification was explored.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
A. S. Mansfield, Z. Wei, R. Mehra, A. T. Shaw, C. H. Lieu, P. M. Forde, A. E. Drilon, E. P. Mitchell, J. J. Wright, N. Takebe, E. Sharon, D. Hovelson, S. Tomlins, J. Zeng, K. Poorman, N. Malik, R. J. Gray, S. Li, L. M. McShane, L. Rubinstein, D. Patton, P. M. Williams, S. R. Hamilton, B. A. Conley, C. L. Arteaga, L. N. Harris, P. J. O'Dwyer, A. P. Chen, K. T. Flaherty
Summary: The NCI-MATCH study aims to evaluate the efficacy of targeted therapies in histology-agnostic malignancies with driver mutations. It was found that patients with rare tumors harboring ALK or ROS1 rearrangements may respond to crizotinib treatment.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Ian E. Krop, Opeyemi A. Jegede, Juneko E. Grilley-Olson, Josh D. Lauring, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Scott A. Kono, James M. Ford, Agustin A. Garcia, Xingwei D. Sui, Robert D. Siegel, Brian M. Slomovitz, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Summary: The study found that Taselisib monotherapy had limited activity in heavily pretreated cancer patients with PIK3CA-mutated tumors. The presence of a PIK3CA mutation alone does not appear to be a sufficient predictor of Taselisib activity.
JCO PRECISION ONCOLOGY
(2022)
Article
Oncology
Senthil Damodaran, Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John J. Wright, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Jennifer M. Suga, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Summary: This study evaluated the clinical activity of copanlisib in patients with PIK3CA mutations. The results showed that copanlisib demonstrated therapeutic efficacy in refractory tumors with PIK3CA mutations.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Susan N. Chi, Joanna S. Yi, P. Mickey Williams, Sinchita Roy-Chowdhuri, David R. Patton, Brent D. Coffey, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd A. Alonzo, Stacey L. Berg, Nilsa C. Ramirez, Alok Jaju, Joyce C. Mhlanga, Elizabeth Fox, Douglas S. Hawkins, Margaret M. Mooney, Naoko Takebe, James Tricoli, Katherine A. Janeway, Nita L. Seibel, D. Williams Parsons
Summary: The National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice conducted phase II trials of molecularly targeted therapies for pediatric patients with refractory solid tumors, brain tumors, lymphomas, and histiocytic disorders. Treatment with the EZH2 inhibitor tazemetostat showed a 5% objective response rate, but 25% of patients with multiple histologic diagnoses experienced prolonged stable disease. These results suggest that tazemetostat may have a potential effect on disease stabilization.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Olive S. Eckstein, Carl E. Allen, P. Mickey Williams, Sinchita Roy-Chowdhuri, David R. Patton, Brent Coffey, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd A. Alonzo, Stacey L. Berg, Nilsa C. Ramirez, Alok Jaju, Joyce Mhlanga, Elizabeth Fox, Douglas S. Hawkins, Margaret M. Mooney, Naoko Takebe, James Tricoli, Katherine A. Janeway, Nita L. Seibel, D. Williams Parsons
Summary: In the NCI-COG Pediatric MATCH trial, the MEK inhibitor selumetinib showed limited efficacy in treating pediatric patients with treatment-refractory tumors harboring MAPK alterations. The study highlights the importance of individualized treatments for pediatric cancers.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Philippe L. Bedard, Shuli Li, Kari B. Wisinski, Eddy S. Yang, Sewanti A. Limaye, Edith P. Mitchell, James A. Zwiebel, Jeffrey A. Moscow, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Summary: This study evaluated the efficacy and safety of afatinib in patients with ERBB2-activating mutations. The results showed that afatinib did not meet the prespecified threshold for antitumor activity in heavily pretreated patients, but showed notable response in a rare tumor type.
JCO PRECISION ONCOLOGY
(2022)
Article
Oncology
James M. Cleary, Victoria Wang, Rebecca S. Heist, E. Scott Kopetz, Edith P. Mitchell, James A. Zwiebel, Kevin S. Kapner, Helen X. Chen, Shuli Li, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, Funda Meric-Bernstam, Melissa S. Dillmon, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Andrew J. Aguirre, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty
Summary: The study suggests that single-agent binimetinib did not show significant efficacy in NRAS-mutated cancers, but observed increased overall survival and progression-free survival in patients with NRAS codon 61-mutated colorectal cancer warrant further investigation.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do, Jennifer Zlott, Ashley Bruns, Lawrence Rubinstein, Jared C. Foster, Lamin Juwara, Robert Meehan, Richard Piekarz, Howard Streicher, Elad Sharon, Naoko Takebe, Andrea Regier Voth, Donald Bottaro, Rene Costello, John J. Wright, James H. Doroshow, Alice P. Chen
Summary: In this study, the efficacy of single-agent cabozantinib in treating advanced soft-tissue sarcomas (STS) was evaluated. The results showed that cabozantinib exhibited antitumor activity in selected STS histologic subtypes, highlighting the biomolecular diversity of STS.
CLINICAL CANCER RESEARCH
(2022)
Meeting Abstract
Oncology
Patrick Walsh McGarrah, Jennifer Gile, Alex John Liu, Aaron Scott Mansfield, Konstantinos Leventakos, Aakash Desai, Sri Harsha Tella, Bassam Bassam Sonbol, Jason S. Starr, Timothy J. Hobday, Thorvardur Ragnar Halfdanarson
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Anne S. Tsao, Harvey Pass, Andreas Rimner, Aaron S. Mansfield
Summary: Malignant pleural mesothelioma (MPM) is a rare malignancy with limited treatment options. Recent advances have led to changes in treatment standards, including the use of a novel biomedical device in combination with platinum-pemetrexed and the inclusion of immunotherapy as a frontline treatment option. Proper identification of the MPM histology is crucial in determining the optimal treatment plan. Immunotherapy can benefit all MPM patients and should be considered at some point during treatment. Ongoing research is focusing on defining frontline therapy in the unresectable setting and addressing immunotherapy refractory cases.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Senthil Damodaran, Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John J. Wright, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Jennifer M. Suga, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Summary: This study evaluated the clinical activity of copanlisib in patients with PIK3CA mutations. The results showed that copanlisib demonstrated therapeutic efficacy in refractory tumors with PIK3CA mutations.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Ti Wen, Whitney Barham, Ying Li, Henan Zhang, Joanina K. Gicobi, Jacob B. Hirdler, Xin Liu, Hyoungjun Ham, Kodi E. Peterson Martinez, Fabrice Lucien, Roxane R. Lavoie, Hu Li, Cristina Correia, Dileep D. Monie, Zesheng An, Susan M. Harrington, Xiaosheng Wu, Ruifeng Guo, Roxana S. Dronca, Aaron S. Mansfield, Yiyi Yan, Svetomir N. Markovic, Sean S. Park, Jie Sun, Hong Qin, Minetta C. Liu, George Vasmatzis, Daniel D. Billadeau, Haidong Dong
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Oncology
Anja C. Roden, Sagar Rakshit, Geoffrey B. Johnson, Sarah M. Jenkins, Aaron S. Mansfield
Summary: The expression of SSTR2 in neuroendocrine tumors and carcinomas plays a role in imaging studies and guiding therapy. In this study, SSTR2 expression in TET was correlated with 68Ga-DOTATATE PET/CT or 68Ga-DOTATATE PET/MR results and treatment outcome. The findings suggest that 68Ga-DOTATATE PET scans are useful in identifying TET patients who may be amenable to treatment with somatostatin analogues.
FRONTIERS IN ONCOLOGY
(2022)
Editorial Material
Oncology
Anuhya Kommalapati, Aaron S. Mansfield
Summary: The activity of KRAS inhibitors against brain metastases is not well studied. Recent preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial suggest that adagrasib (MRTX849) has the potential to penetrate the central nervous system and provide control of KRAS(G12C) brain metastases.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Dai Chihara, Erich P. Huang, Shanda R. Finnigan, Lisa M. Cordes, Nebojsa Skorupan, Yoko Fukuda, Larry Rubinstein, S. Percy Ivy, James H. Doroshow, Loretta J. Nastoupil, Christopher R. Flowers, Naoko Takebe
Summary: In the past two decades, the development of cancer drugs has shifted from cytotoxic chemotherapy to targeted treatment. This study analyzed patient-level data from phase I trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program to assess the trend of toxicity and response rates for patients with hematologic malignancies over time. The study found that the overall response and complete response rates improved significantly, while the rate of toxicity-related death remained stable.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Daniel P. Wickland, Mark E. Sherman, Derek C. Radisky, Aaron S. Mansfield, Yan W. Asmann
Summary: In the United States, cancer disparities among Black and African American individuals are affected by genetic factors. This study compared the qualities of germline and tumor exomes between African and European patients in The Cancer Genome Atlas. The results showed that African patients had lower sequencing depth, leading to underdetection and lower quality of variants. Consideration of epidemiological factors is crucial for future genomics studies.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Farhad Kosari, Maria Disselhorst, Jun Yin, Tobias Peikert, Julia Udell, Sarah Johnson, James Smadbeck, Stephen Murphy, Alexa McCune, Giannoula Karagouga, Aakash Desai, Janet Schaefer-Klein, Mitesh J. Borad, John Cheville, George Vasmatzis, Paul Baas, Aaron S. Mansfield
Summary: This study found that the interaction between tumor junction burdens and antigen presentation gene sets in mesothelioma patients is associated with overall survival, providing further insight into the potential mechanisms of immunotherapy.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Editorial Material
Oncology
Katherine E. R. Smith, Aaron Mansfield
Article
Oncology
Michael T. Schweizer, Roman Gulati, Todd Yezefski, Heather H. Cheng, Elahe Mostaghel, Michael C. Haffner, Radhika A. Patel, Navonil De Sarkar, Gavin Ha, Ruth Dumpit, Brianna Woo, Aaron Lin, Patrick Panlasigui, Nerina McDonald, Michael Lai, Katie Nega, Jeannette Hammond, Petros Grivas, Andrew Hsieh, Bruce Montgomery, Peter S. Nelson, Evan Y. Yu
Summary: This study investigated the use of Bipolar androgen therapy (BAT) in metastatic castration-resistant prostate cancer (mCRPC) and found that BAT plus olaparib combination therapy can achieve high response rates and long progression-free survival. The clinical effects of this treatment may be related to DNA damage induction and synergy with PARP inhibitors. The presence or absence of HRR gene mutations does not affect the efficacy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Meeting Abstract
Oncology
A. Dimou, Y. -C. Lo, K. Halling, A. S. Mansfield
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Pedro Luiz Serrano Uson Junior, Umair Majeed, Jun Yin, Gehan Botrus, Mohamad Bassam Sonbol, Daniel H. Ahn, Jason S. Starr, Jeremy C. Jones, Hani Babiker, Samantha R. Inabinett, Natasha Wylie, Ashton W. R. Boyle, Tanios S. Bekaii-Saab, Gregory J. Gores, Rory Smoot, Michael Barrett, Bolni Nagalo, Nathalie Meurice, Natalie Elliott, Joachim Petit, Yumei Zhou, Mansi Arora, Chelsae Dumbauld, Oumar Barro, Alexander Baker, James Bogenberger, Kenneth Buetow, Aaron Mansfield, Kabir Mody, Mitesh J. Borad
Summary: This study aimed to evaluate the prognostic value of pretreatment circulating tumor DNA (ctDNA) in metastatic biliary tract cancers (BTCs) treated with platinum-based chemotherapy. The results showed that DCAF > 3% was associated with worse overall survival (OS). Stratifying DCAF into quartiles, DCAF > 10% was significantly related to worse progression-free survival (PFS) and OS. Each 1% increase in ctDNA was associated with a decrease in survival probabilities.
JCO PRECISION ONCOLOGY
(2022)
Article
Oncology
Ian E. Krop, Opeyemi A. Jegede, Juneko E. Grilley-Olson, Josh D. Lauring, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Scott A. Kono, James M. Ford, Agustin A. Garcia, Xingwei D. Sui, Robert D. Siegel, Brian M. Slomovitz, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Summary: The study found that Taselisib monotherapy had limited activity in heavily pretreated cancer patients with PIK3CA-mutated tumors. The presence of a PIK3CA mutation alone does not appear to be a sufficient predictor of Taselisib activity.
JCO PRECISION ONCOLOGY
(2022)